# Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma

> **NCT03215719** · PHASE2 · RECRUITING · sponsor: **NYU Langone Health** · enrollment: 120 (estimated)

## Conditions studied

- Oropharyngeal Carcinoma
- HPV Positive Oropharyngeal Squamous Cell Carcinoma

## Interventions

- **RADIATION:** Standard Radiation Treatment
- **RADIATION:** Dose-Deescalated Treatment
- **DRUG:** Cisplatinum

## Key facts

- **NCT ID:** NCT03215719
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-10-18
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03215719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03215719, "Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT03215719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*